Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Farrell

Showing results (31-40 of 172) with videos related to

Pageof 18
Sort By:
The Journal of Infection|September 14, 2010
The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)David J Farrell, Mariana Castanheira, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutationsDavid J Farrell, Jemma Shackcloth, Karen A Barbadora, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Heterogeneous macrolide resistance and gene conversion in the pneumococcusNicole Wolter, Anthony M Smith, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|March 26, 2003
Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong KongIan Morrissey, David J Farrell, Sarah Bakker, et al.
The Journal of Infection|June 14, 2005
Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3Stephen G Jenkins, David J Farrell, Manish Patel, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI StudyEliana S Armstrong, David J Farrell, Melissa Palchak, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2016
Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014David J Farrell, Rodrigo E Mendes, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|July 27, 2004
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutationsDavid J Farrell, Ian Morrissey, Sarah Bakker, et al.
International Journal of Antimicrobial Agents|March 30, 2010
In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial speciesDavid J Farrell, Marion Robbins, William Rhys-Williams, et al.
Diagnostic Microbiology and Infectious Disease|February 11, 2012
Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolonesMariana Castanheira, Lalitagauri M Deshpande, Ronald N Jones, et al.
Pageof 18

Showing results (31-40 of 172) with videos related to

Sort By:
Pageof 18
The Journal of Infection|September 14, 2010
The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)David J Farrell, Mariana Castanheira, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutationsDavid J Farrell, Jemma Shackcloth, Karen A Barbadora, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Heterogeneous macrolide resistance and gene conversion in the pneumococcusNicole Wolter, Anthony M Smith, David J Farrell, et al.
Antimicrobial Agents and Chemotherapy|March 26, 2003
Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong KongIan Morrissey, David J Farrell, Sarah Bakker, et al.
The Journal of Infection|June 14, 2005
Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3Stephen G Jenkins, David J Farrell, Manish Patel, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI StudyEliana S Armstrong, David J Farrell, Melissa Palchak, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2016
Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014David J Farrell, Rodrigo E Mendes, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|July 27, 2004
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutationsDavid J Farrell, Ian Morrissey, Sarah Bakker, et al.
International Journal of Antimicrobial Agents|March 30, 2010
In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial speciesDavid J Farrell, Marion Robbins, William Rhys-Williams, et al.
Diagnostic Microbiology and Infectious Disease|February 11, 2012
Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolonesMariana Castanheira, Lalitagauri M Deshpande, Ronald N Jones, et al.
Pageof 18